| Celecoxib (n= 28,614) | nsNSAID (n= 15,278) | Placebo (n= 5,827) | Rofecoxib (n= 1,329) | Total (n= 51,048) |
---|---|---|---|---|---|
Age, years | Â | Â | Â | Â | Â |
   Mean, SD | 60.1 (13) | 59.3 (13) | 57.2 (14) | 70.6 (9) | 59.8 (13) |
   ≥ 65 years, n (%) | 11,404 (40) | 5,667 (37) | 1,901 (33) | 1,115 (84) | 20,087 (39) |
   ≥ 75 years, n (%) | 3,421 (12) | 1,656 (11) | 513 (9) | 460 (35) | 6,050 (12) |
Female, n (%) | 18,819 (66) | 10,478 (69) | 3,251 (56) | 860 (65) | 33,408 (65) |
Indication | Â | Â | Â | Â | Â |
   OA/RA, n (%) | 23,324 (82) | 13,911 (91) | 3,074 (53) | 1,329 (100) | 41,638 (82) |
Low-back pain, n (%) | 1,743 (6) | 850 (6) | 1,042 (18) | 0 (0) | 3,635 (7) |
Ankylosing spondylitis, n (%) | 895 (3) | 517 (3) | 232 (4) | 0 (0) | 1,644 (3) |
   Alzheimer disease, n (%) | 329 (1) | 0 (0) | 158 (3) | 0 (0) | 487 (1) |
   Oncology, n (%) | 2,323 (8) | 0 (0) | 1,321 (23) | 0 (0) | 3,644 (7) |
Duration, n (%) | Â | Â | Â | Â | Â |
≤ 12 weeks | 15,597 (55) | 8,322 (55) | 3,871 (66) | 1,245 (94) | 29,035 (57) |
> 12 and ≤ 26 weeks | 7,878 (28) | 4,271 (28) | 675 (12) | 84 (6) | 12,908 (25) |
> 26 and ≤ 52 weeks | 2,307 (8) | 1,958 (13) | 90 (2) | 0 (0) | 4,355 (9) |
≥ 52 weeks | 2,832 (10) | 727 (5) | 1,191 (20) | 0 (0) | 4,750 (9) |
Total patient-years of exposure | 12,276.3 | 4,621.8 | 3,755.6 | 154.5 | 20,808.2 |
100 patient-years of exposure | 122.8 | 46.2 | 37.6 | 1.6 | 208.1 |